The interplay between inflammation, dense stromal tissue, and local aromatase expression also suggests that there may be a role for non-steroidal anti-inflammatory drugs (NSAIDs) in improving our ability to diagnose breast cancer in diabetic women. This evidence concerns the gene CYP19A1 and breast carcinoma.